Viatris EBITDA 2010-2025 | VTRS

Viatris annual and quarterly EBITDA history from 2010 to 2025. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Viatris EBITDA for the quarter ending March 31, 2025 was $0.719B, a 19.62% decline year-over-year.
  • Viatris EBITDA for the twelve months ending March 31, 2025 was $2.728B, a 16.63% decline year-over-year.
  • Viatris 2024 annual EBITDA was $2.903B, a 17.21% decline from 2023.
  • Viatris 2023 annual EBITDA was $3.507B, a 24.47% decline from 2022.
  • Viatris 2022 annual EBITDA was $4.643B, a 3.8% increase from 2021.
Viatris Annual EBITDA
(Millions of US $)
2024 $2,903
2023 $3,507
2022 $4,643
2021 $4,473
2020 $2,005
2019 $2,735
2018 $3,016
2017 $3,243
2016 $2,222
2015 $2,493
2014 $1,919
2013 $1,652
2012 $1,656
2011 $1,516
2010 $1,144
2009 $925
Viatris Quarterly EBITDA
(Millions of US $)
2025-03-31 $719
2024-12-31 $566
2024-09-30 $896
2024-06-30 $546
2024-03-31 $895
2023-12-31 $190
2023-09-30 $1,131
2023-06-30 $1,056
2023-03-31 $1,130
2022-12-31 $668
2022-09-30 $1,260
2022-06-30 $1,271
2022-03-31 $1,443
2021-12-31 $672
2021-09-30 $1,375
2021-06-30 $1,269
2021-03-31 $1,156
2020-12-31 $72
2020-09-30 $784
2020-06-30 $550
2020-03-31 $600
2019-12-31 $820
2019-09-30 $793
2019-06-30 $597
2019-03-31 $525
2018-12-31 $842
2018-09-30 $839
2018-06-30 $681
2018-03-31 $654
2017-12-31 $945
2017-09-30 $760
2017-06-30 $895
2017-03-31 $643
2016-12-31 $790
2016-09-30 $315
2016-06-30 $714
2016-03-31 $403
2015-12-31 $765
2015-09-30 $859
2015-06-30 $535
2015-03-31 $334
2014-12-31 $561
2014-09-30 $629
2014-06-30 $355
2014-03-31 $374
2013-12-31 $415
2013-09-30 $467
2013-06-30 $427
2013-03-31 $343
2012-12-31 $391
2012-09-30 $506
2012-06-30 $384
2012-03-31 $374
2011-12-31 $372
2011-09-30 $407
2011-06-30 $406
2011-03-31 $331
2010-12-31 $207
2010-09-30 $339
2010-06-30 $297
2010-03-31 $301
2009-12-31 $164
2009-09-30 $165
2009-06-30 $273
2009-03-31 $322
Sector Industry Market Cap Revenue
Medical Medical Services $10.727B $14.739B
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
Stock Name Country Market Cap PE Ratio
Danaher (DHR) United States $141.524B 26.54
CVS Health (CVS) United States $81.417B 10.12
Elevance Health (ELV) United States $76.834B 9.91
Cencora (COR) United States $57.577B 20.03
DiDi Global (DIDIY) China $25.180B 26.75
Natera (NTRA) United States $21.599B 0.00
Labcorp Holdings (LH) United States $20.908B 16.96
BioMerieux (BMXMF) France $16.861B 0.00
EUROFINS SCIENT (ERFSF) Luxembourg $13.318B 0.00
CochLear (CHEOY) Australia $13.009B 0.00
Solventum (SOLV) United States $12.815B 13.57
ICON (ICLR) Ireland $12.075B 11.23
Revvity (RVTY) United States $11.607B 19.97
Medpace Holdings (MEDP) United States $9.208B 24.45
Avantor (AVTR) United States $9.009B 13.09
Sonic Healthcare (SKHHY) Australia $8.842B 0.00
HealthEquity (HQY) United States $8.418B 36.87
Charles River Laboratories (CRL) United States $7.762B 15.21
Caris Life Sciences,�Inc (CAI) United States $7.052B 0.00
Amplifon S.p.A (AMFPF) Italy $5.378B 29.44
Bausch + Lomb (BLCO) Canada $4.840B 28.50
BrightSpring Health Services (BTSG) United States $3.571B 32.76
Sotera Health (SHC) United States $3.296B 18.73
Surgery Partners (SGRY) United States $2.880B 37.45
Alignment Healthcare (ALHC) United States $2.651B 0.00
Concentras Parent (CON) United States $2.593B 14.98
Organon (OGN) United States $2.550B 2.71
GeneDx Holdings (WGS) United States $2.351B 90.54
Ardent Health (ARDT) United States $2.073B 8.84
Progyny (PGNY) United States $2.012B 44.28
PACS (PACS) United States $1.966B 0.00
Premier (PINC) United States $1.750B 13.28
GoodRx Holdings (GDRX) United States $1.725B 34.50
Teladoc Health (TDOC) United States $1.451B 0.00
Establishment Labs Holdings (ESTA) $1.316B 0.00
Pediatrix Medical (MD) United States $1.131B 8.60
CareDx (CDNA) United States $1.115B 17.41
Ryman Healthcare (RYHTY) New Zealand $0.970B 0.00
Agilon Health (AGL) United States $0.931B 0.00
QDM (QDMI) Hong Kong, SAR China $0.848B 291.00
AMN Healthcare Services Inc (AMN) United States $0.791B 7.41
Nutex Health (NUTX) United States $0.645B 9.76
Embecta (EMBC) United States $0.606B 4.08
InnovAge Holding (INNV) United States $0.582B 0.00
SBC Medicals (SBC) United States $0.518B 0.00
LifeMD (LFMD) United States $0.514B 0.00
Sonida Senior Living (SNDA) United States $0.487B 0.00
Auna S.A (AUNA) Luxembourg $0.473B 10.65
Omada Health (OMDA) $0.452B 0.00
So-Young (SY) China $0.430B 0.00
Enhabit (EHAB) United States $0.359B 29.50
COMPASS Pathways (CMPS) United Kingdom $0.347B 0.00
Performant Healthcare (PHLT) United States $0.331B 0.00
Oncology Institute (TOI) United States $0.286B 0.00
Beauty Health (SKIN) United States $0.236B 0.00
DocGo (DCGO) United States $0.149B 24.33
Pheton Holdings (PTHL) China $0.142B 0.00
Sera Prognostics (SERA) United States $0.104B 0.00
Ascend Wellness Holdings (AAWH) United States $0.078B 0.00
KindlyMD (NAKA) United States $0.073B 0.00
NeueHealth (NEUE) United States $0.061B 0.00
IceCure Medical (ICCM) Israel $0.060B 0.00
Basel Medical Group (BMGL) Singapore $0.056B 0.00
ModivCare (MODV) United States $0.047B 0.00
Biodesix (BDSX) United States $0.046B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.036B 0.00
OSR Holdings (OSRH) United States $0.022B 0.00
Intelligent Bio Solutions (INBS) United States $0.012B 0.00
Co-Diagnostics (CODX) United States $0.009B 0.00
BioNexus Gene Lab (BGLC) $0.007B 0.00
SeaStar Medical Holding (ICU) United States $0.006B 0.00
XWELL (XWEL) United States $0.005B 0.00
Aclarion (ACON) United States $0.004B 0.00
NewGenIvf Group (NIVF) Thailand $0.003B 0.00
ISpecimen (ISPC) United States $0.003B 0.00
INVO Fertility (IVF) United States $0.002B 0.00
Cano Health (CANOQ) United States $0.000B 0.00